-+ 0.00%
-+ 0.00%
-+ 0.00%

ULTRAGENYX PHARMACEUTICAL: WILL GRANT ESJAY A NON-EXCLUSIVE, ROYALTY-FREE LICENSE TO MARKET ITS GENERIC VERSION OF DOJOLVI BEGINNING JANUARY 1, 2033

Reuters·08/11/2026 12:35:35

Please log in to view news